financetom
Business
financetom
/
Business
/
ABM Industries Tops Second-Quarter Sales Views, Maintains Fiscal 2025 Earnings Outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
ABM Industries Tops Second-Quarter Sales Views, Maintains Fiscal 2025 Earnings Outlook
Jun 6, 2025 6:22 AM

08:57 AM EDT, 06/06/2025 (MT Newswires) -- ABM Industries' ( ABM ) fiscal second-quarter results rose on a yearly basis, with revenue topping market expectations, while the facility solution provider reiterated its full-year earnings outlook.

The company reported adjusted earnings of $0.86 a share for the quarter ended April, in line with the consensus on FactSet, up from $0.82 the year before. Revenue increased 4.6% to $2.11 billion, surpassing the Street's view for $2.06 billion.

For fiscal 2025, ABM Industries ( ABM ) continues to project adjusted EPS to be in a range of $3.65 to $3.80, while the Street is looking for $3.77.

"We remain constructive on the outlook for our core markets, particularly high-quality office buildings, manufacturing and distribution facilities, commercial aviation, and microgrids," Chief Executive Scott Salmirs said in a statement. "Further, projects delayed in the second quarter are expected to be realized in the third quarter."

Revenue in the business and industry segment rose 2.6% to $1.02 billion in the second quarter, buoyed by improving conditions in the company's prime commercial office markets, according to Salmirs. Manufacturing and distribution sales rose 2.4% to $398.1 million, reflecting new "client wins" and favorable comparisons with the prior year, the company said.

Aviation revenue grew 9.2%, while the technical solutions division climbed 19%, though it was weighed down by some "unfavorable timing" on certain projects, Salmirs said.

"Additionally, we secured $1.1 billion in new bookings through the first half of the year, an 11% increase year over year," Salmirs said in the earnings release. "We also produced significant sequential improvement in cash flow as we made important strides in deploying our enterprise resource planning system across the (business and industry) and (manufacturing and distribution) segments."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Beyond Oil Announces First Distribution Agreement in Vietnam
Beyond Oil Announces First Distribution Agreement in Vietnam
Sep 29, 2025
11:59 AM EDT, 09/29/2025 (MT Newswires) -- Beyond Oil ( BEOLF ) Monday announced its entry into the Vietnamese market through a new distribution agreement with Trang Anh Manufacturing and Trading. The distribution agreement, dated Sept. 26, 2025, marks Beyond Oil's ( BEOLF ) first commercial presence in Vietnam. It has an initial term of five years and requires the...
LGI Homes Foreclosure Rates 4x Higher Than FHA Average, Hunterbrook Report Alleges
LGI Homes Foreclosure Rates 4x Higher Than FHA Average, Hunterbrook Report Alleges
Sep 29, 2025
Shares of homebuilder LGI Homes Inc ( LGIH ) are trading lower Monday morning after a report by Hunterbrook Media accused the company of luring renters into buying homes they cannot afford through deceptive marketing and aggressive sales tactics. What To Know: The report, titled “Buyer’s Remorse,” alleges LGI Homes ( LGIH ) targets low-income individuals with ads for unrealistically...
Genmab's $8 Billion Bid Represents 'Good Deal' for Merus' Petosemtamab, Truist Says
Genmab's $8 Billion Bid Represents 'Good Deal' for Merus' Petosemtamab, Truist Says
Sep 29, 2025
11:38 AM EDT, 09/29/2025 (MT Newswires) -- Genmab's ( GMAB ) $8 billion offer for Merus (MRUS) represents a good deal that largely reflects the value of Merus' petosemtamab as a treatment for head and neck cancer, Truist Securities said in a Monday note. The all-cash transaction was announced earlier today, under which a Genmab ( GMAB ) unit will...
MoonLake's SLK Showed Limited Effectivesness in Recent Trials, Impacting Sales, Commercial Outlook, RBC Says
MoonLake's SLK Showed Limited Effectivesness in Recent Trials, Impacting Sales, Commercial Outlook, RBC Says
Sep 29, 2025
11:31 AM EDT, 09/29/2025 (MT Newswires) -- MoonLake Immunotherapeutics' ( MLTX ) SLK showed limited effectiveness in treating hidradenitis suppurativa which is likely to impact its sales and potential in other competitive markets like psoriatic arthritis, RBC Capital Markets said in a note Monday. SLK's phase 3 trial in hidradenitis suppurativa produced mixed results, with one study reaching statistical significance...
Copyright 2023-2026 - www.financetom.com All Rights Reserved